SUNNYVALE, Calif. – Startup Memora Health has developed an artificial intelligence health coach, Felix, to support patients when they return home from the hospital. “A smartphone app that tracks your medication adherence and vital signs over time is hardly the coaching needed to make meaningful lifestyle changes,” said Nisarg Patel, CEO of Memora Health, in a recent blog post. “Patients need someone they can talk to, that can answer their questions, that can work with them day by day, one step at a time. Felix’s features an AI engine that allows a personalization and a conversational interface to simplify the patient user experience. Patients can use the SMS interface on any cell phone to talk to Felix to receive information and care support, ask questions about their treatment, mention challenges they’re facing, and report symptoms and side effects. The platform’s analytics engine identifies potentially dangerous symptoms from patient responses and can alert the patient, caregivers and clinicians in the event of an emergency. Felix is active 24/7 and immediately responds to patient questions and concerns to help them feel cared for at anytime, anywhere, and gets smarter as he talks to and learns from more patients. “Through our new platform, patients receive handcrafted chronic illness support and coaching, proactive medication and appointment reminders, treatment and drug information, and personalized follow-up questions to track patient-reported health outcomes, all personalized to their condition and treatments via text message,” said Patel.
LONDON – Health technology artificial intelligence company Medopad has raised $28 million in Series A funding toward a target of $120 million. The company’s health care technology data-capture platform connects patients and health care professionals in real time, enabling patients to continuously capture data through a broad set of modules and connected devices, then transmitting the collected data to health care professionals. “We now have several amazing strategic investors in the business, which is a great achievement for us as we gear up for significant growth and scale our business,” said Dan Vahdat, CEO of Medopad, in a statement. “Managing population health is one of the greatest challenges for governments across the world; we are proud to be at the forefront of solving this problem.” By improving the communication between patients and healthcare professionals, Medopad enables proactive early intervention, operational efficiencies and cost savings. The platform uses artificial intelligence to analyze collected data and develop predictive insights to detect life-threatening medical conditions. The company’s primary customers include hospitals, pharma companies, insurance companies and governments. Medopad has also announced that it has appointed industry leaders Stuart Fletcher, former CEO of BUPA Group, and Simon MacKinnon, chairman of Sinophi Healthcare, as non-executive directors.
BRISBANE, Australia, and BOSTON – M3DICINE Inc, designers of intelligent medical devices, has launched Stethee, an artificial intelligence-enabled stethoscope system. “This most iconic and enduring symbol of health care is now reinvented into an intelligent and sophisticated medical device—a powerful diagnostic assistant that becomes more intelligent the more it is used,” said Dr. Nayyar Hussain, founder and CEO of M3DICINE, in a statement. “The complementary Stethee apps bring the power of machine learning and deep neural networks to health professionals worldwide who can use this data not only to monitor the progress and health of individual patients, but collectively to uncover new patterns and trends to help in the fight against heart and lung disease globally.” The technology platform behind Aida, the Stethee AI engine, can analyze heart and lung sounds to build a unique personal biometric signature. Aida also automatically tags geo-location and environmental data to each sample in real-time. The platform analyzes the encrypted data to learn and report back quantitative clinically actionable data to health care professionals.
SAN FRANCISCO & LONDON – Bupa, an international health and care company, and HealthTap, an artificial intelligence-powered network of interactive doctors, have announced a long-term strategic partnership to deploy combination digital and in-person healthcare. HealthTap’s proprietary health operating system, HOPES, and its AI-powered apps will enable Bupa digital experiences and enhance speed, convenience and quality of care for Bupa customers. “I believe our partnership with HealthTap will deliver truly innovative health care solutions to improve the lives of Bupa customers globally,” said Evelyn Bourke, CEO of Bupa Group, in a statement. “Over the past year we have worked together to implement a number of solutions for day-to-day customer needs; together we bring world-leading digital health and care experiences to our customers, while saving costs and delivering efficiencies for health care providers.”
REDWOOD CITY, Calif. — Health care technology company Biotricity is working with a proof of concept version of its remote patient monitoring hardware embedded with artificial intelligence as it seeks to differentiate itself in the growing remote monitoring marketplace. “We plan on implementing artificial intelligence at the device level to maximize detection and accuracy while increasing efficiency,” said Waqaas Al-Siddiq, founder and CEO of Biotricity, in a statement. “We expect our next generation Bioflux device with artificial intelligence capabilities to be the first of its kind in the RPM marketplace.” The company plans to file an additional hardware clearance with the U.S. Food and Drug Administration this year, before launching the next version.
BOSTON and TOKYO – Partners Connected Health and Hitachi are working together to develop artificial intelligence technology which can accurately predict the risk of hospital readmissions within 30 days for patients with heart failure.
“With this innovation, doctors and nurses using the algorithm will be able to tell exactly why a certain patient is at high risk for hospital admission, and what they can do about it,” said Dr. Kamal Jethwani, senior director, Partners Connected Health Innovation, in a statement. “We want to enable our providers to act on this information, which is a step beyond the state-of-the-art today, in terms of machine learning algorithms.”
The AI technology helps select appropriate patients to participate in a readmission prevention program following hospital discharge, and can explain the reason why patients were identified as being at high risk.
The technology is an example of explainable AI, a new term currently defined as enabling machines to explain their decisions and actions to human users, and enabling them to understand, appropriately trust and effectively manage AI tools, while maintaining a high level of prediction accuracy.
As part of the study, the Partners Connected Health Innovation team simulated the readmission prediction program among heart failure patients participating in the Partners Connected Cardiac Care Program, a remote monitoring and education program designed to improve the management of heart failure patients at risk for hospitalization.
Hitachi’s new AI technology uses deep learning to construct the prediction model. The company developed the technology for risk prediction with analyzing the results presented by deep learning and extracting the several dozens of actionable factors for each patient from the vast amount of data collected from heart failure patients. Through a standard statistical approach based on this risk prediction model, the extracted factors were used to calculate the risk of hospital readmission, and the relevance of the factors was calculated. Thus, this explainable AI technology can enhance prediction accuracy and the quality of medical decision-making.
Hitachi and the Partners Connected Health Innovation team will jointly conduct a prospective study, which evaluates the prediction program by clinicians, and study how to integrate this within clinical workflows.
LAS VEGAS and LONDON – Accenture has completed a three-month pilot program that uses artificial intelligence and voice technology to help older people manage their care delivery and well-being. The Accenture Liquid Studio in London developed the AI-powered Accenture Platform that can learn user behaviors and preferences and suggest activities to support the overall physical and mental health of individuals ages 70 and older. The platform, which runs on the Amazon Web Services cloud, includes a Family and Carer portal that lets family and caregivers check on the individual’s daily activities, and can also spot abnormalities in behavior and alert family or friends, based on user defined permissions. “We are working closely with Accenture and other Amazon Partner Network partners to help people have access to the benefits AI can bring,” said Dr. Matt Wood, general manager for Deep Learning and AI at AWS, in a statement. The Accenture Platform’s combination of voice activation, on-screen prompts and underlying cloud-based AI technology provided the participants with new ways of doing a range of tasks and extending their well-being.
CAMBRIDGE, Mass. and EAST GREENWICH, R.I. – Provant, a provider of comprehensive workplace well-being solutions, has adopted Twine Health’s technology to help people manage their health more effectively. Twine Health’s artificial intelligence-powered SaaS platform is currently being used by 56 workplace health providers and health care delivery systems, combining a self-management app and a centralized console enabling health coaches to deliver personalized services. “We looked at a number of options, but Twine’s state- of-the-art technology and focus on coaching as a central component of care set it apart from anything else we saw,” said Tom Basiliere, CIO for Provant, in a statement.
ATLANTA – A new collaborative initiative aims to use machine learning to better identify people living with chronic obstructive pulmonary disease who are at risk of exacerbations and hospitalization.
Health care technology company Jvion is collaborating with the COPD Foundation, the Geisinger health system and pharmaceutical company GSK to leverage cognitive machine technology and data for patients with COPD.
“The best way to prevent readmission is to prevent admission in the first place,” said Dr. Paul Simonelli, director of thoracic medicine at Geisinger. “This initiative will help us identify who is sick enough with COPD to be at risk of admission and how we can prevent it.”
The goal of the initiative is to use Jvion’s Cognitive Clinical Success Machine to identify COPD patients currently under the care of Geisinger who are at risk of hospitalization and most likely to benefit from new medications. The CCSM is an advanced artificial intelligence solution built using an Eigen Spheres engine that uses patient mapping to enable a comprehensive patient view that is amplified beyond the risk of an event to the clinical actions that will improve outcomes and drive patient engagement.
The initiative, funded by GSK, is divided into two phases: phase one will target COPD patients who have had an inpatient stay and who are at risk of a readmission within 30 days of their initial discharge; phase two will focus on identifying COPD patients at-risk of an avoidable hospitalization.
“This is a huge win for us,” said Craig Kephart, CEO of the COPD Foundation, who said the organization has had multiple requests over the years from health care providers looking for information on best practices to prevent readmissions and exacerbations, and preserve lung function for people with COPD. “Developing these algorithms will help to personalize treatment a little more.”
LONDON – Biopharmaceutical company Merck Sharp & Dohme and the accelerator Wayra UK have kicked off the third Velocity Health program to award up to $90,000 to two digital health startups using artificial intelligence and machine learning to support disease and illness prevention. Velocity Health was set up in 2015 to invest in digital innovation in healthcare to address the challenges outlined in the National Health Service’s Five Year Forward View. Previous programs focused on prevention in health care with an emphasis on diabetes prevention and cancer prevention. “Velocity Health 2018 aims to build on the achievements of the previous two years of Velocity Health and work with start-ups that truly complement the future of healthcare delivery,” said Dr. Junaid Bajwa, director of health care services at MSD, in a statement. “The NHS has made digital excellence the cornerstone of its future model and we must embrace this if we are to have a healthcare system fit for the 21st Century.”